Published in Heart Disease Weekly, March 26th, 2006
According to researchers working in the United States, "A major limitation of stem cell transfer is early donor-cell death. [In our report], we seek to enhance myocardial repair following injury through transplantation of cardiomyocyte-enriched human embryonic stem cells (hESC) and recipient treatment with cytoprotective (allopurinol + uricase) and anti-inflammatory (ibuprofen) agents."
"We injected 106 (15% hESC-derived cardiomyocytes) green fluorescent protein (GFP+) hESC in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Heart Disease Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.